Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)

Figures & data

Figure 1. OS and PFS of uveal melanoma patients treated with ipilimumab 3 mg/kg. All uveal melanoma patients treated in the Dutch expanded access program were evaluated retrospectively for OS (red, Figure 1A) and PFS (blue, Figure 1B) All 22 patients were included for PFS analysis, and the patients not evaluable at week 12 were defined to be progressive at the date of clinical deterioration. The detailed follow-up of the patients during treatment is shown in Figure 1C.

Table I. Response to treatment.

RECIST after 12 weeks
Progressive disease	13 (59.1%)
Stable disease	0 (0%)
Partial response	1 (4.5%)
Complete response	0 (0%)
Not evaluable	8 (36.4%)
IRRC after 12 weeks
Progressive disease	12 (54.5%)
Stable disease	1 (4.5%)
Partial response	1 (4.5%)
Complete response	0 (0%)
Not evaluable	8* (36.4%)
Best overall response
Progressive disease	12 (54.5%)
Stable disease	1 (4.5%)
Partial response	1 (4.5%)
Complete response	0 (0%)
Not evaluable	8* (36.4%)
Clinical benefit (based on BOR)
PD/NE	20 (90.9%)
SD > 24w/PR/CR	2 (9.1%)
Response rate (based on BOR)
SD/PD/NE	21 (95.5%)
CR/PR	1 (4.5%)

*Not evaluable due to fast disease progression and death within 65 days after start of treatment.